About Sony Biotechnology

  • A Message from Sony Biotechnology Regarding the COVID-19 Situation

    Sony Biotechnology is closely monitoring the COVID-19 situation across the globe. Our first priority is to ensure the health and safety of our employees in affected areas around the world. We are reviewing guidance from the World Health Organization (WHO), US Centers for Disease Control and Prevention (CDC), government agencies, and health officials in a variety of affected countries.

    More

  • Pulmonary Cardiology: Circulating Immune Cells and the Pathogenesis of Pulmonary Arterial Hypertension

    Cardiopulmonary diseases represent a significant health burden for many countries around the world. It is therefore vital to accelerate research toward the development of new therapies to treat these diseases. In this article, we talk to researchers at Queen’s University, Ontario, Canada, about the new Queen’s CardioPulmonary Unit (QCPU) core facility and research center, and how studying endothelial dysfunction, mitochondrial biology, and specific gene mutations is improving the understanding of the molecular factors influencing diseases of the lung vasculature, such as pulmonary arterial hypertension (PAH).

    More

  • Sony MA900 Cell Sorter Nominated for Best New Life Sciences Product of 2018!

    The Sony MA900 Multi-Application Cell Sorter has been nominated for the Best New Life Sciences Product of 2018 in the Scientists' Choice Awards.

    More

  • Cystic Fibrosis Foundation Therapeutics in Boston BizJournal

    The Cystic Fibrosis Foundation Therapeutics Inc. has opened a new laboratory in Lexington, MA. and will be using the Sony SH800 for cell sorting. The lab will focus on the discovery of promising drugs for both common and rare mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

    More